<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489631</url>
  </required_header>
  <id_info>
    <org_study_id>TKP-37796</org_study_id>
    <nct_id>NCT01489631</nct_id>
  </id_info>
  <brief_title>Analgesia After Total Knee Replacement Surgery</brief_title>
  <official_title>Comparison of Intra-articular Infiltration and Gabapentin With Epidural Analgesia After Total Knee Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pain after total knee replacement surgery is difficult to treat. Mobilisation&#xD;
      and hospital discharge might be delayed. Recent research shows that intra-articular&#xD;
      infiltration with local anesthetics and perioperative prescription of gabapentin can improve&#xD;
      outcome.&#xD;
&#xD;
      Objective of the study: Comparison of mobilisation speed and postoperative NRS-scores of&#xD;
      patients after total knee replacement surgery which is treated with epidural analgesia or&#xD;
      peroperative infiltration of the knee. Appraisal of the value of gabapentin for reduction of&#xD;
      postoperative opiate consumption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      Prospective randomised study&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients aged eighteen years or older, in whom knee replacement surgery is indicated. They&#xD;
      will have spinal anaesthesia and epidural analgesia if indicated by randomisation. They must&#xD;
      not have contraindications for epidural analgesia or the used medication in this study.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      The first group will be treated with epidural analgesia. Before surgery the epidural catheter&#xD;
      will be placed according to local guidelines. After the operation epidural infiltration with&#xD;
      bupivacaine and sufentanil will be commenced. The second group will receive local&#xD;
      infiltration with ropivacaine of the knee during surgery. Half of these patients will&#xD;
      additionally be treated with gabapentin.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      NRS-score (11-scale Numeric Rating Scale in which 0 means no pain, and 10 means most pain&#xD;
      imaginable) in rest.&#xD;
&#xD;
      Secondary study parameters/outcome of the study:&#xD;
&#xD;
      Speed of mobilisation, postoperative opiate consumption. NRS scores during flexion exercise&#xD;
      of the knee and during walking exercise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS score in rest</measure>
    <time_frame>3 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speed of mobilisation</measure>
    <time_frame>3 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>3 days after surgery</time_frame>
    <description>Daily morphine consumption (mg) per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS score during flexion exercise</measure>
    <time_frame>3 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS score during walking exercise</measure>
    <time_frame>3 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>epidural analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>local infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The second group will receive local infiltration with ropivacaine of the knee during surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>local infiltration and gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naropin</intervention_name>
    <description>ropivacaine 0,2%, 3x 50 ml during surgery</description>
    <arm_group_label>local infiltration</arm_group_label>
    <arm_group_label>local infiltration and gabapentin</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>marcaine</intervention_name>
    <description>bupivacaine 0,125%</description>
    <arm_group_label>epidural analgesia</arm_group_label>
    <other_name>bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>sufentanil 1mcg/ml</description>
    <arm_group_label>epidural analgesia</arm_group_label>
    <other_name>sufenta forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neurontin</intervention_name>
    <description>gabapentin 600 mg pre-operative 3 dd 300 mg</description>
    <arm_group_label>local infiltration and gabapentin</arm_group_label>
    <other_name>gabapentin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older and legally responsible&#xD;
&#xD;
          -  Waiting for total knee replacement surgery&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for epidural analgesia&#xD;
&#xD;
          -  Aortic Valve stenosis&#xD;
&#xD;
          -  Severely compromised cardiac function&#xD;
&#xD;
          -  infection near epidural punction site&#xD;
&#xD;
          -  Redo knee surgery&#xD;
&#xD;
          -  Previous arthrotomies&#xD;
&#xD;
          -  Allergy/Hypersensitivity for study mediation or all other used medication&#xD;
&#xD;
          -  Participation in other studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon Timmerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis N Marting, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic surgeon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Leon Timmerman</investigator_full_name>
    <investigator_title>anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Epidural</keyword>
  <keyword>Local infiltration</keyword>
  <keyword>Knee</keyword>
  <keyword>Arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

